SGLT2 inhibitors and GLP1 receptor antagonists improve type-2 diabetes outcomes, but are not cost effective

A cost-effectiveness study of sodium–glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP1) receptor agonists has found that the use of these medications as first-line treatment for type-2 diabetes would improve outcomes, but their costs would need to decrease by at least 70 percent to be cost-effective. The study is published in Annals of Internal Medicine.

source https://medicalxpress.com/news/2022-10-sglt2-inhibitors-glp1-receptor-antagonists.html